Summit Therapeutics Share Discussion Threads

[freemoney1] 12/10/2016 11:22

Hi Chaps, just created my user here. I've been on LSE since investing in Summit in 2011 (I think it was 2011 - what a long time ago!) but that board is being trolled too heavily now so no meaningful discussion is allowed to happen.
Anyway just thought I'd introduce myself and say I'm looking forward to some very exciting months ahead as we hopefully broker a C.Diff deal and see positive PhaseOut data coming through in Q2/3 next year. Roll on the £20 party! GLA

[hugus maximus] 11/10/2016 11:19

The Sarepta Finance BB's are finally discussing Summit's work. An interesting example here of how they view the PPMD Joint conference call (I quote verbatim without correction!):

"stocktrooth • 17 hours ago Flag

Summary of PPMD conference call: Sarepta and Summit

Summit will continue to execute the clinical trials. Phase 2 begins shortly in the US

Made completely new utrophin modulator compound (S6) with work with Oxford. 10 boys will get S6 in the US in the PhaseOut study. The extension study will be of the compound that performs the best S3 vs. S6.

Summit wanting a development program, with a single trial (carried out in US and Europe), that can satisfy both FDA and EMA approval.

Not going to test combination therapy. Remain focused on single engine activity until both are proven.

Sarepta to study 6 months to 4 years old group in Europe. Previously they've only looked at as low as 4 years old.

Summit not interested in studying older patients (older than 18). Instead, they'd rather conduct trials on young homogenous groups and receive approval so all age groups can have access.

Summit doesn't have a compassionate use policy but will need a level of efficacy and safety before it does so within the confines of clinical trials.

Sarepta doesn't have compassionate use policy either to focus on meeting all the regulatory commitments with all their ongoing trials.

Summit not worried about getting combination therapy in future in either EMA or FDA as other fields, such as cancer drugs, this is a common place.

Sarepta and Summit partnership not brand new. Their research teams have collaborated with animal testing and biopsies to share lessons learned. Summit is looking for, and Sarepta offers, regulatory expertise.

Utrophin produced during growth and in event of injury. "As muscle damage occurs then the utrophin turns off. When no dystrophin arrives then utrophin turns back on." They're finding high amounts of natural utrophin in DMD patients but it's patchy in biopsies.

Sarepta has the sites that perform the biopsies to first process a piece of steak to prove they're capable of processing the biopsy exactly the same way before human biopsy is performed.

Ed Kaye acknowledges MRI is a far distant surrogate marker."

[chrisatrdg] 10/10/2016 20:36

Summit Therapeutics Retweeted this evening.

MuscularDystrophyUK ‏@MDUK_News 1h1 hour ago
Join us Wednesday 6-7pm to put your Qs on #utrophin to Prof Dame Kay Davies & Richard Pye from @Summitplc #Duchenne hxxp://qoo.ly/bcxji

[freedosh] 10/10/2016 20:10

Fibonacci was misnamed. Fibonacci numbers should be called Filius Bonacci numbers - he was the son of Bonacci
Just a load of old rabbits really

[someuwin] 10/10/2016 20:00

Added Sarepta charts to the header.

[luminoso] 10/10/2016 19:09

Yes looks like consolidation happening over the water. Fibonacci has spoken and hopefully moved on. No idea what he knew about shares anyway.... thought he played for Inter Milan in the 70s !

[hugus maximus] 10/10/2016 18:23

Interesting to see that there seems to be more general resistance to the share price being pounded on the NASDAQ, and as many have suggested, perhaps the american market may be reaching a grounding on which there's some potential to build? The thought of seeing my shares (averaging 163p)in the red again is just so boring.

Being here for the long haul, it's actually unimportant what happens to the share price over the next few months, as it's DMD P2 trial results end of 2017 that will see significant returns.

But it would be nice to pop in here from time to time, and see some general share price progress!

[chrisatrdg] 10/10/2016 17:20

A reminder from the other board by 'laylou' today:

'Hi everyone, Well its been an exciting few days... I wondered how folk were feeling after todays trading?

Just to remind everyone ......End Duchenne.org website 'PPMD will be hosting a community update call with Sarepta and Summit on Monday, October 10 at 12:00pm EDT to answer any of your questions' see website for dial in details and email address to send questions....GLA'

[someuwin] 10/10/2016 15:53

Summit Therapeutics ‏@Summitplc · 45 minutes ago

Trial locations and statuses for our PhaseOut DMD clinical trial have been updated on … #utrophin #Duchenne

[joeblogg2] 10/10/2016 15:28

Crazy almost back to where we were befre the deal :(((

[someuwin] 10/10/2016 14:53

Summit Therapeutics ‏@Summitplc · 33 minutes ago

We're having a call 2day 4 the #Duchenne community w/ Sarepta & @ParentProjectMD 2 answer Qs about our collaboration

[hugus maximus] 10/10/2016 11:54

Waterloo - many thanks. Indeed I didn't clock that the FDX versus RDZ test may have european results available in the 4th Q. (Whilst the USA continue on to year end with results due Feb 2017)

Surely if as hoped there is significant improvement of RDZ over FDX, this could be of interest to Merck who must have large sums of money available if they with to continue superiority in the C Diff field?

[patviera] 10/10/2016 11:27

Thanks footballAppreciate it

[luminoso] 10/10/2016 10:16

Thanks for that, football.

[sorrento06] 09/10/2016 23:21

We were told to expect news on RDZ in August, so I maintain it could come at anytime

[hugus maximus] 09/10/2016 09:26

RDZ verses FDX tests currently saying :

"Estimated Study Completion Date: February 2017
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)"



So perhaps no further C Diff developments until above?

[waterloo01] 08/10/2016 16:36

US recruitment open. RNS Monday?



Edit: I note that in addition to the US and Canada we have kept most of the rest of the English speaking world including Australia, India and all of Asia. As we get closer, each of those area rights will have increasing value.

[football] 08/10/2016 15:50

Solomon could always post the Daily Mail link it on a US message board so they can see it

;)

[solomon] 08/10/2016 13:28

Waterloo, normally such a mention in the Daily Mail would create a new wave of interest. However, the Nasdaq traders might not read the Daily Mail. :-/

[waterloo01] 08/10/2016 09:45

Fibonacci gives me an idea of how this stock will behave. Along with the Volume MA and other indicator such us the bottom plots, I believe this stock is forecasted to go down for a few days before it goes back up. Wait for future indicators and to be below 10.3$ to enter (if you want to be conservative). Also, keep an eye open for news. This stock is fairly new and I believe it has potential to grow.

[waterloo01] 08/10/2016 09:18

For the junior biotech the Holy Grail is taking a drug all the way from the lab to the market – in the US they call it hitting a home run and the achievement is usually transformational. Unfortunately, very few home runs have been hit here in the UK, even though we have a very active drug development sector.
That’s because the costs of developing a new treatment are prohibitive as they can run to hundreds of millions of pounds – and of course success is not guaranteed.

Often the next best thing is to find a big brother with pockets deep enough to fund the work required to get a new discovery through the R&D phase to the pharmacists’ shelves. That’s exactly what Summit Therapeutics managed this week. It brokered a licensing deal worth more than half a billion dollars with an American firm called Sarepta.
It won’t receive that cash all at once, but at points during the clinical testing of the firm’s potentially breakthrough new drug for Duchenne Muscular Dystrophy, a muscle wasting disease that affects boys.

Summit will get £32million upfront, followed by £18million once the last patient in the company’s phase II clinical trial is dosed.
Unsurprisingly, the Sarepta deal moved the dial, pushing the share price 50 per cent higher. Analysts think it will go further.

[chrisatrdg] 07/10/2016 16:38

Summit and Sarepta: The key questions answered




X proactive X investors

xx PROACTIVITY